Skip to content
logo-cevidra-small
  • Home
  • Company
    • About Us
    • Our Team
    • They Trust Us
    • Join Us
  • Exploitant Status
  • Services
    • Early Access Programs
    • Compassionate Use and Named Patient Programs in France
    • Market Access
    • Post-Market Surveillance
    • Supply Chain Optimization
    • Promotion & Sales
  • Expertise
    • Advanced Therapy Medicinal Products
    • Blood Derived Products
    • Orphan Drugs & Rare Diseases
    • Opioid Addiction
    • Hospital Market
    • Regulatory Compliance
  • Contact
  • English
    • French
Previous Next

What is the role of HAS in early access programs in France?

HAS assesses and grants early access authorizations for innovative medicines, ensuring timely patient access. (Haute Autorité de Santé)

2025-10-29T17:13:31+02:00October 23, 2025|Early Access, France Market Insights|Comments Off on What is the role of HAS in early access programs in France?

Share This Story, Choose Your Platform!

XRedditLinkedInWhatsAppEmailCopy Link
logo-cevidra-small

FIND US

Aroma, Parc d’activités, 45 Bd Marcel Pagnol, 06130 Grasse

Mon-Fri: 9:00 AM – 6:00 PM

  • +33 (0) 4 93 70 58 31

  • contact@cevidra.com

OUR SERVICES

Discover our main services to help you address the French Market.

Market Access
The Exploitant Status
Post Market Surveillance
Supply Chain Optimization
Promotion & Sales

OUR EXPERTISE

We operate in the following areas of expertise.

Orphan Drugs
Hospital Market

Blood Derived products

ATMPs

Regulatory Compliance

© Copyright 2025 | Cevidra | All Rights Reserved | Privacy | Legal | FAQ | Glossary

Page load link
  • English
  • Français
Go to Top